Barclays PLC Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Barclays PLC grew its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 281.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,218 shares of the company's stock after acquiring an additional 28,208 shares during the quarter. Barclays PLC owned about 0.08% of Mineralys Therapeutics worth $463,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SG Americas Securities LLC bought a new position in Mineralys Therapeutics in the 3rd quarter valued at $110,000. China Universal Asset Management Co. Ltd. grew its stake in Mineralys Therapeutics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock valued at $116,000 after purchasing an additional 3,732 shares during the period. Federated Hermes Inc. grew its stake in Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after purchasing an additional 6,000 shares during the period. PDT Partners LLC bought a new position in Mineralys Therapeutics in the 3rd quarter valued at $148,000. Finally, The Manufacturers Life Insurance Company bought a new position in Mineralys Therapeutics in the 2nd quarter valued at $145,000. Institutional investors own 84.46% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Tuesday, November 12th.

Insider Activity

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total transaction of $382,994.46. Following the completion of the transaction, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. The trade was a 15.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total value of $97,888.70. Following the transaction, the chief financial officer now owns 226,097 shares of the company's stock, valued at $2,057,482.70. The trade was a 4.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 54,572 shares of company stock worth $646,980 in the last quarter. 33.24% of the stock is owned by company insiders.

Mineralys Therapeutics Price Performance

NASDAQ MLYS traded down $0.26 during trading on Friday, reaching $9.24. The company's stock had a trading volume of 234,826 shares, compared to its average volume of 186,831. The firm has a fifty day moving average of $12.18 and a 200 day moving average of $12.45. Mineralys Therapeutics, Inc. has a one year low of $7.95 and a one year high of $16.91. The stock has a market capitalization of $459.87 million, a PE ratio of -2.83 and a beta of 1.49.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its quarterly earnings data on Monday, November 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same period last year, the firm posted ($0.57) earnings per share. Research analysts expect that Mineralys Therapeutics, Inc. will post -3.63 earnings per share for the current fiscal year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.